BRIGHT MINDS BIOSCIENCES INC

DRUGNASDAQ

Earnings Aug 13US Equity

$80.25▼ $0.54 (−0.67%)

🌙 After hours$80.25▲ 0.00%Regular close · extended-hours price shown

1h—

24h▼ 0.7%

7d—

14d—

30d—

1y—

🏦Market Cap

$787M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

No chart data available for DRUG.

Trading Snapshot

Day Range: $79.78 – $81.10
52-Week Range: —
Volume: $5.20B
Avg Volume: $4.80B
Shares Outstanding: 9.8M
Next Earnings: Sep 2, 2026

Fundamentals Snapshot

Annual Revenue: $100M
Last Q Revenue: $23M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): —
Dividend Yield: —

Why Investors Own DRUG

✓High-growth profile — revenue up +47.4% YoY with expanding US Equity exposure.
✓Healthy economics — 73% gross margin and 10% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$100M▲ +50.6% YoY

Gross Margin (TTM)

72.5%▲ +4.2% YoY

Operating Income (TTM)

$18M▲ +50.6% YoY

Free Cash Flow (TTM)

$10M▲ +50.6% YoY

About BRIGHT MINDS BIOSCIENCES INC

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

🦦